Exploratory Study on NAD+ Measurement Techniques Following NMN (Two Types) Intake

Evaluation and Validation Study Using Specific Analytical Methods to Assess the Pharmacokinetics of NMN (two types) Following a Single Oral Dose: A Parallel Study - Validation Testing of Analytical Techniques for NMN (two types)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000061927

Enrollment

Registered

2026-06-17

Start date

2026-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

Type 1 NMN 350mg Type 2 NMN 250mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Healthy individuals 2.Individuals who, having fully understood the purpose and content of the study, consent to participate of their own free will

Exclusion criteria

Exclusion criteria: 1.Individuals with an acute illness or currently undergoing treatment for such an illness 2.Individuals with a blood disorder 3.Individuals currently suffering from a symptomatic infectious disease on the test day 4.Individuals who regularly consume health supplements containing NMN 5.Individuals who are pregnant or breastfeeding 6.Individuals currently participating in other clinical trials or similar studies 7.Any other individuals deemed unsuitable as subjects by the treating physician or the principal investigator

Design outcomes

Primary

Measure	Time frame
Changes in Whole blood NAD levels over time	—

Secondary

Measure	Time frame
Changes in whole blood NMN-related metabolites (eight types) levels over time	—

Countries

Japan

Contacts

Public ContactNami Harada

DHC Corporation Supplements Unit

nharada@dhc.co.jp0432754811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026